Anbio Biotechnology Class A Ordinary Shares
Anbio Biotechnology provides in vitro diagnostics (IVD) products in the European Union, the Asia Pacific, North America, South America, Africa, and internationally. It offers SARS-CoV-2 antigen rapid and SARS-CoV-2/influenza A/B antigen rapid tests; and lateral flow immunoassay, fluorescence immunoassay, loop-mediated isothermal amplification, chemiluminescence immunoassay, and reverse-transcription polymerase chain reaction products. It serves over-the-counter, point-of-care testing, and laboratory markets. The company was incorporated in 2021 and is based in Frankfurt am Main, Germany.
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2025 Q4 | 0.07 | $5M | — |
| 2025 Q2 | 0.09 | $5M | — |
| 2024 Q4 | -0.03 | $3M | $2M |
| 2024 Q2 | 0.09 | $6M | $647,540 |
| 2023 Q4 | 0.02 | $4M | -$1M |
| 2023 Q2 | 0.04 | $3M | $2M |